Lahjavida, Inc.
Lahjavida is a pioneering cancer research company focused on developing innovative dye drug conjugates for targeted cancer therapy. Their mission is to improve and extend the gift of life for cancer patients by creating safer, more effective treatments that precisely target tumors while protecting healthy tissues. With over 25 years of expertise in tumor-targeting dye technology and a strategic approach combining dyes, linkers, and chemotherapy drugs, Lahjavida aims to revolutionize cancer care across multiple cancer types, including metastatic tumors.
Industries
Nr. of Employees
small (1-50)
Lahjavida, Inc.
Colorado Springs, Colorado, United States, North America
Products
Dye–Drug Conjugate (DDC) platform
A small-molecule platform that links a tumor-targeting near-infrared dye to standard chemotherapy drugs via a cleavable linker; designed to remain inactive in circulation, preferentially accumulate in tumors, and release active drug intracellularly.
Dye–Drug Conjugate (DDC) platform
A small-molecule platform that links a tumor-targeting near-infrared dye to standard chemotherapy drugs via a cleavable linker; designed to remain inactive in circulation, preferentially accumulate in tumors, and release active drug intracellularly.
Services
Preclinical development and testing
Design and execution of in vitro (2D), organoid, and in vivo studies to assess tumor targeting, penetration, efficacy, and toxicity of conjugates.
Conjugate synthesis and research-scale manufacturing
Synthesis and small-batch manufacture of dye–drug conjugates and dye–gold conjugates for preclinical experimentation.
Imaging and biodistribution studies (NIR)
Near-infrared imaging to track systemic distribution, tumor accumulation, retention and clearance of conjugates in preclinical models.
Academic collaboration and advisory support
Research partnerships and advisory engagement with university laboratories and clinical researchers to independently test and validate conjugate performance.
Preclinical development and testing
Design and execution of in vitro (2D), organoid, and in vivo studies to assess tumor targeting, penetration, efficacy, and toxicity of conjugates.
Conjugate synthesis and research-scale manufacturing
Synthesis and small-batch manufacture of dye–drug conjugates and dye–gold conjugates for preclinical experimentation.
Imaging and biodistribution studies (NIR)
Near-infrared imaging to track systemic distribution, tumor accumulation, retention and clearance of conjugates in preclinical models.
Academic collaboration and advisory support
Research partnerships and advisory engagement with university laboratories and clinical researchers to independently test and validate conjugate performance.
Expertise Areas
- Targeted drug delivery
- Tumor-targeting dye development
- Nanoparticle-mediated hyperthermia
- Preclinical research (organoids and animal models)
Key Technologies
- Near-infrared (NIR) fluorescent dyes
- Cleavable linker chemistry
- Gold nanoparticle conjugation (~20 nm)
- Radiowave-induced nanoparticle heating